Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials by Weinblatt, M, Taylor, P, Burmester, G, Saifan, C, Walls, C, Issa, M, Rooney, T, Takeuchi, T

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis by Weinblatt, M, Taylor, P, Burmester, G, Witt, S, Saifan, C, Walls, C, Rooney, T, Chen, L, Takeuchi, T

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: result... by Tanaka, Y, Weinblatt, M, Taylor, PC, Fleischmann, R, Ishizuka, T, Tanaka, M, Takita, Y, Schlichting, D, Takeuchi, T

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis by Weinblatt, M, Taylor, P, Keystone, E, Ortmann, R, Issa, M, Xie, L, de Bono, S, Tanaka, Y

OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. by Taylor, P, Genovese, M, Greenwood, M, Ho, M, Nasonov, E, Oemar, B, Stoilov, R, Vencovsky, J, Weinblatt, M

Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies by Taylor, PC, Chen, YF, Pope, J, Weinblatt, M, Mysler, E, Rubbert-Roth, A, Jia, B, Sun, L, Liu, Y, Holzkämper, T, Tanaka, Y

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate by Taylor, P, Emery, P, Weinblatt, M, Mysler, E, Rubbert-Roth, A, Jia, B, Sun, L, Liu, Y, Chen, Y, Cardoso, A, Tanaka, Y

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis by Taylor, P, Weinblatt, M, Burmester, G, Rooney, T, Witt, S, Walls, C, Issa, M, Salinas, C, Saifan, C, Zhang, X, Cardoso, A, Gonzalez-Gay, M, Takeuchi, T

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study by Emery, P, Taylor, P, Weinblatt, M, Tanaka, Y, Keystone, E, Dow, E, Higgs, R, Macias, W, Rocha, G, Rooney, T, Schlichting, D, Zuckerman, S, McInnes, I

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study by Keystone, E, Taylor, P, Tanaka, Y, Gaich, C, DeLozier, A, Dudek, A, Zamora, J, Covarrubias Cobos, J, Rooney, T, de Bono, S, Arora, V, Linetzky, B, Weinblatt, M

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis by Smolen, JS, Taylor, PC, Tanaka, Y, Takeuchi, T, Hashimoto, M, Cara, C, Lauwerys, B, Tilt, N, Ufuktepe, B, Xavier, RM, Balsa, A, Curtis, JR, Mikuls, TR, Weinblatt, M

Baricitinib contre placebo ou adalimumab chez des patients atteints de polyarthrite rhumatoïde (PR) active et présentant une réponse inadéquate au méthotrexate (MTX) : Résultats d’... by Taylor, P, Keystone, E, Van Der Heijde, D, Tanaka, Y, Ishii, T, Emoto, K, Yang, L, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, De Bono, S, Weinblatt, M, Combe, B

Development of a multi-biomarker disease activity test for rheumatoid arthritis by Centola, M, Cavet, G, Shen, Y, Ramanujan, S, Knowlton, N, Swan, K, Turner, M, Sutton, C, Smith, DR, Haney, D, Chernoff, D, Hesterberg, L, Carulli, J, Taylor, P, Shadick, N, Weinblatt, M, Curtis, JR

Baricitinib versus placebo or adalimumab in rheumatoid arthritis by Taylor, P, Keystone, E, Van der Heijde, D, Weinblatt, M, del Carmen Morales, L, Reyes Gonzaga, J, Yakushin, S, Ishii, T, Emoto, K, Beattie, S, Arora, V, Gaich, C, Rooney, T, Schlichting, D, Macias, W, de Bono, S, Tanaka, Y

Anti–GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3) by Taylor, PC, Weinblatt, M, McInnes, IB, Atsumi, T, Strand, V, Takeuchi, T, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Fleischmann, R

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomise... by Fleischmann, R, van der Heijde, D, Strand, V, Atsumi, T, McInnes, IB, Takeuchi, T, Taylor, PC, Bracher, M, Brooks, D, Davies, J, Goode, C, Gupta, A, Mukherjee, S, O’Shea, C, Saurigny, D, Schifano, L, Shelton, C, Smith, JE, Wang, M, Wang, R, Watts, S, Weinblatt, M